---
title: Assessment Tool Scoring and Key Takeaways
description: See your 90/10 Assessment results and discover where your patient engagement infrastructure has gaps.
---

![copy-1](https://243587507.hs-sites-na2.com/hs-fs/hubfs/copy-1.png?width=1408&height=597&name=copy-1.png "copy-1")

# Thank you for taking your assessment.

Review what your score means, key insights, and clear next steps below.

[Helpful? Let’s connect and keep the conversation going](https://www.linkedpatientlearning.com/contact?webInteractiveId=740329534200&webInteractiveContentId=321356584657&containerType=MODAL&pageUrl=https%3A%2F%2F243587507.hubspotpreview-na2.com%2F_hcms%2Fpreview%2Fpreview-interactive%3FpreviewInteractiveId%3D321356584657%26_preview%3Dtrue%26portalId%3D243587507%26tc_deviceCategory%3Ddesktop&portalId=243587507)

![](https://7528302.fs1.hubspotusercontent-na1.net/hub/7528302/hubfs/raw_assets/public/mV0_d-cms-elevate-theme_hubspot/elevate/images/step-one.png?width=140&height=140&name=step-one.png)

# Score 0-3

(Major 90% Infrastructure Gaps)

What This Means

Your patient engagement infrastructure is heavily optimized for the 10% (activation)—enrollment, benefit verification, initial training. But you have limited visibility into the 90% of the patient journey where persistence is actually determined. 

The Impact

Without visibility into the 90%, you likely experience:

- High discontinuation rates you can't explain
- Patient frustration with handoffs you don't see
- Inability to intervene before patients stop therapy
- Vendor metrics that look good while outcomes lag

 What to Do Next

**Immediate Action:** Map where your patient journey handoffs are breaking. Before you add another vendor or platform, understand where the 90% gaps exist.

**Strategic Action:** Rethink your infrastructure using the 90/10 Framework. You need ecosystem-level visibility, not just more point solutions

![](https://7528309.fs1.hubspotusercontent-na1.net/hub/7528309/hubfs/raw_assets/public/mV0_d-cms-elevate-theme_hubspot/elevate/images/step-two.png?width=140&height=140&name=step-two.png)

# Score 4-7

(Optimizing for the 10%)

What This Means

You have some visibility into the 90%, but your infrastructure is still primarily designed for activation moments. You likely have point solutions that work well individually but don't create a coherent patient experience across the ecosystem. 

The Impact

You're better than most, but you're still:

- Reacting to problems instead of preventing them
- Managing vendors instead of patient journeys
- Unable to test and learn systematically
- Missing the early warning signs of discontinuation

 What to Do Next

**Immediate Action:** Identify which handoffs create the most friction. You don't need to fix everything—start with the one or two places where patients struggle most between your vendor touchpoints.

**Strategic Action:** Shift from vendor management to ecosystem design. You have good building blocks; they need to be connected around the patient experience, not vendor scopes

![](https://7528309.fs1.hubspotusercontent-na1.net/hub/7528309/hubfs/raw_assets/public/mV0_d-cms-elevate-theme_hubspot/elevate/images/step-three.png?width=140&height=140&name=step-three.png)

# Score 8-10

(You Understand the 90%)

What This Means

You're rare. You've built infrastructure that addresses the full patient journey—not just activation moments. You have ecosystem-level visibility, proactive intervention capability, and accountability for patient experience across vendors 

The Opportunity

You understand the 90%. Now the question is execution:

- Are you measuring the ROI of your 90% infrastructure?
- Can you connect this infrastructure to business outcomes for CFOs and payers?
- Are you using this as competitive differentiation?

 What to Do Next

**Immediate Action:** Document what's working. You've solved the infrastructure problem most pharma companies struggle with—this is your competitive advantage.

**Strategic Action:** Build the business case. Your 90% infrastructure should translate to measurable improvements in persistence, real-world evidence, and cost-per-persistent-patient.